FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Friday

 

Biomarkers of Early MS and Overactive Bladder Identified in New Study


Researchers at the University of Athens Medical School in Greece have found that people with early stage multiple sclerosis (MS) and overactive bladder (OAB) have reductions in brain serotonin and a stress-related hormone, cortisol. Serotonin is a chemical that helps nerve cells to communicate. The study, titled “Neurochemical and neuroendocrine correlates of overactive bladder at first demyelinating episode“ appeared July 30th in the journal Neurourology and Urodynamics.

MS is a debilitating, progressive disease of the nervous system. It is caused by an immune attack on the body’s own myelin, a fatty substance that wraps around nerve cells and allows them to conduct impulses and communicate. When myelin is lost, areas of damage called “demyelination” result, which appear in the brain and spinal cord without warning and cause loss of movement, vision, pain and problems with sensation.

Bladder problems also occur frequently in people with MS, with approximately 75% of individuals with MS suffering from this problem. In fact, OAB may be a sign of a first MS episode.

The control of urination is complicated and involves many different components of the nervous system, including the brain, spinal cord and peripheral nervous system. Problems with urination are also experienced by people with anxiety and depression, which are conditions that are more prevalent in people with MS.

The scientists, led by Georgios Koutsis of the Department of Neurology, University of Athens Medical School, were interested in understanding what biological markers are associated with early stage MS and OAB. They studied 101 people with MS and a first demyelinating episode, which is an initial sign of MS onset. They assessed the study participants for signs of OAB and measured several biomarkers in the cerebral spinal fluid of these individuals. The biomarkers included neurotransmitters as well as stress hormones.

Overall, 15 study subjects (15%) had OAB. In those people a breakdown product of the neurotransmitter serotonin (5-HIAA) was reduced when compared to people who did not have OAB. These subjects also had lower levels of the stress hormone cortisol.

In their report, the scientists state “MS patients with OAB syndrome at the first demyelinating episode show reductions in central serotonergic activity and stress hormones. Whether the same changes persist at later disease stages remains to be investigated.”

In future studies the investigators will examine whether these decreases also continue in people with OAB at later MS stages. The biomarkers could potentially be used clinically to identify people with MS and OAB and also to indicate a subgroup of those individuals who have MS.


Story Source: The above story is based on materials provided by MULTIPLESCLEROSISNEWSTODAY
Note: Materials may be edited for content and length

Labels:



Go to Newer News Go to Older News